Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Sonoma Pharmaceuticals, Inc. on September 16, 2026. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol SNOA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Voting Results
Out of 4,788,425 shares entitled to vote, 2,082,799 shares were present or represented by proxy. Stockholders approved the following proposals:
- Proposal 1 (Election of Class III Director): Mr. Jerry McLaughlin was elected with 336,722 votes for and 20,198 votes withheld.
- Proposal 2 (Advisory Vote on Executive Compensation): Approved for the fiscal year ended March 31, 2026, with 286,312 votes for, 38,559 against, and 32,049 abstentions.
- Proposal 3 (Ratification of Auditors): Frazier & Deeter, LLC was ratified as the independent registered public accounting firm for the fiscal year ending March 31, 2027, with 2,063,173 votes for, 12,522 against, and 7,104 abstentions.
- Proposal 4 (Adjournment to Solicit Additional Proxies): Approved with 1,797,076 votes for, 119,486 against, and 166,237 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items beyond the standard voting procedures.
Key Facts for Investor Verification
- Verify the total number of shares outstanding and the percentage of shares represented at the meeting (approximately 43.5%).
- Confirm the tenure and background of the newly elected Class III director, Jerry McLaughlin.
- Review the definitive proxy statement filed on July 28, 2026, for details on executive compensation and auditor fees.
- Check subsequent filings for the company's financial results for the fiscal year ended March 31, 2026, as they are not included in this 8-K.